Never miss an important update

Click    to get notified about important updates only.   

99 push-notification-bg

99 Alternatives

We are sorry that you have opted out.

However, if you accidentally selected "Block" or you want to receive notifications in the future, then follow any of the following instructions.

Option 1

99 chrome-b-n

Option 2

1. visit to Chrome > Settings > Content Settings

2. click here Content Settings > Notifications > Manage Exceptions

OR

Copy & Paste in Addrsss Bar > "chrome://settings/content/notifications?search=notif"

3. Select Allow for https://www.99alternatives.com/

4. Refresh the page.

99 Alternatives

Opportunities are Infinite

Please wait
99 Alternative logo
Business
All Categories

Investors Space-Spreading Awareness

Join a community that's informative, communicative & Interactive

99 Alternatives-Taking Initiative

99 top-hearder-guide-book
Register Today to Download Your Free
Alternative Asset Guide for 2020
Worth £49.99 and Free Life Time
Subscription to 99 Alternatives Web Portal
Worth £100's Limited Availability…
register for e Asset Guide
Latest News
Iran rial slides to new low as coronavirus, sanctions weigh
Siemens sees up to 20% drop in business in April-June quarter, CFO tells Boersenzeitung
Swiss could pay off COVID debt pile over 15 years - Finance Minister
Commerzbank fined 650,000 euros for deals with defunct Cypriot bank
Marshall Wace targets $1 billion for new ESG focused fund - source
Shell CEO does not rule out moving headquarters to Britain
Scam Alerts
What Is The Computer Misuse Act?
Call Centre Scams Conning People
The easy way to stop your online accounts getting hacked
Fraudster sentenced after funding luxury holidays through £50k smishing scam
Banking industry stops £4.5 million of fraud a day in first half of 2019
Barclays issues warning to university students, as number of under-21s recruited as money mules..
Interact-With-Prospective-Clients_728x9099 Ads

Japan's Astellas to buy Audentes for $3 billion in gene therapy push

Astellas Pharma's logo is pictured at its headquarters in Tokyo
Share:
TOKYO (Reuters) - Japan's Astellas Pharma Inc has agreed to buy Audentes Therapeutics Inc for about $3 billion in cash as it seeks to make genetic medicines a key area of growth. Gene therapies are one of the hottest areas of drug research and Astellas, Japan's second-largest drugmaker by sales, is offering $60 per share for San Francisco-based Audentes, a 110% premium to its closing price on..
Date Published: Dec 03, 2019
To view the full article, Register Now.
Register Today And Get Your Free Lifetime Elite Subscription Worth £100’s
Are You Already a Member? Login
Natex_728x9099 Ads

Related Articles

300x25099 Ads

Video

Copyright © 2020 99alternatives Ltd.   All rights reserved.

Designed and Managed by Mont Digital